Passar para o conteúdo principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting

Whitepapers

Tech Sheet on Tofacitinib Citrate

Tech Sheet on Tofacitinib Citrate

Tofacitinib Citrate (Xeljanz) is an oral, small molecule drug used to treat adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis, and moderate to severe ulcerative colitis. Tofacitinib works by blocking the body’s production of enzymes called Janus kinases (JAKs). Tofacitinib citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis

The global drug sales of Tofacitinib (Xeljanz®) stood at 2.6 billion USD in 2022 and recorded a historical growth (CAGR) of 22% between 2017 to 2022. In addition, before losing patent protection in 2026, it is expected that Tofacitinib will witness peak sales at $2.8 billion in 2025.

Dr. Reddy's API Offering

  • Crystalline polymorphic form
  • Customized particle size distribution (PSD), which plays a vital role in the formulation development.
  • Our process involves efficient chemical transformations that offer a distinctive advantage concerning quality and manufacturability.

We manufacture Tofacitinib citrate API at our cGMP API manufacturing facility, successfully inspected by international regulatory authorities - USFDA, KFDA, WHO-GMP, Russian federation, and ANVISA (document-based inspection completed and certificate is available).

To know more about our API offerings, please read the Tech sheet on Tofacitinib citrate API by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

Preencha o formulário de contato abaixo para visualizar o white paper

Aviso Legal

Nenhuma informação neste site, incluindo qualquer referência a qualquer produto ou serviço, constitui uma oferta de venda ou pode ser interpretada como representando uma oferta de venda. Produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, em certos casos, a critério exclusivo do Dr. Reddy e sujeito a requisitos legais locais, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissões regulatórias sob a Seção 107A da Lei de Patentes da Índia (isenção Bolar), onde quer que tais isenções regulatórias existam. Os compradores devem fazer sua avaliação independente do produto ou serviço, incluindo o cenário de patentes em seus respectivos mercados e serão responsáveis ​​por todas as responsabilidades relacionadas a patentes. O Dr. Reddy se isenta de todas as garantias, expressas ou implícitas, incluindo, entre outras, garantias de comercialização, adequação a uma finalidade específica e não violação.

Empresa

Contate-Nos

Follow Us on

  • Twitter

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

  • Twitter

© 2025 Dr. Reddy’s Laboratories Ltd.
All rights reserved.

X

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting